Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapies in these patient groups.
According to the findings, there is a hint of a minor added benefit of albiglutide plus metformin in comparison with metformin plus sulfonylurea because hypoglycaemia occurs less frequently.
http://www.sciencedaily.com/releases/2015/01/150108113852.htm
According to the findings, there is a hint of a minor added benefit of albiglutide plus metformin in comparison with metformin plus sulfonylurea because hypoglycaemia occurs less frequently.
http://www.sciencedaily.com/releases/2015/01/150108113852.htm